DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,877,753 B2 Buschmann Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,877,753 B2 Buschmann Et Al US008877753B2 (12) United States Patent (10) Patent No.: US 8,877,753 B2 Buschmann et al. (45) Date of Patent: Nov. 4, 2014 (54) 1-ARYL-3-AMNOALKOXY PYRAZOLES AS (56) References Cited SIGMA LGANDSENHANCING ANALGESC EFFECT OF OPODS AND ATTENUATING FOREIGN PATENT DOCUMENTS THE DEPENDENCY THEREOF EP 1130018 A1 9, 2001 EP 1634872 A1 3, 2006 (75) Inventors: Helmut Heinrich Buschmann, Aachen EP 1829875 A1 9, 2007 (DE); Jose Miguel Vela Hernandez, WO 96.16063 A1 5, 1996 Barcelona (ES); Daniel WO 98.46618 A1 10, 1998 WO 9959409 A1 11, 1999 Zamanillo-Castanedo, Barcelona (ES) WO 2006021462 A1 3, 2006 WO 2006027221 A1 3, 2006 (73) Assignee: Laboratorios Del Dr. Esteve, S.A., Barcelona (ES) OTHER PUBLICATIONS Chih-Cheng Chien et al., “Sigma antagonists potentiate opioid anal (*) Notice: Subject to any disclaimer, the term of this gesia in rats'. Neuroscience Letters, vol. 190, No. 2, 1995, pp. 137 patent is extended or adjusted under 35 139. U.S.C. 154(b) by 629 days. International Search Report for PCT/EP2009/054974, dated Jun. 17, 2009. (21) Appl. No.: 12/988,951 Chien et al., “Selective Antagonism of Opioid Analgesia by a Sigma System”. J. Pharmacol. Exp. Ther: 1994; 271; pp. 1583-1590. Meiet al., “Receptor Modulation of Opioid Analgesia in the Mouse'. (22) PCT Fled: Apr. 24, 2009 J. Pharmacol Exp. Ther.; 2002; 300(4); pp. 1070-1074. Carlsson et al., “Interaction of pentobarbital and morphine in the (86) PCT NO.: PCT/EP2009/054974 tail-flick test performed on rats: Synergism at the spinal and antago nism at the Supraspinal level”, NeuroSci. Lett.; 1986; 71; pp. 356 S371 (c)(1), 360. (2), (4) Date: Dec. 17, 2010 Janicki et al., “Detection of Antagonist Activity for Narcotic Anal gesics in Mouse Hot-Plate Test'. Pharmacol. Biochem. Behavior, 1979; 10(4); pp. 623-626. (87) PCT Pub. No.: WO2009/130310 Jianjing Cao, et al "Dual Probes for the Dopamine Transporter and PCT Pub. Date: Oct. 29, 2009 sigmal Receptors: Novel Piperazinyl Alkyl-bis (4-fluorophenyl)amine Analogues as Potential Cocaine-Abuse Therapeutic Agents'. J. Med. Chem, No. 13, Mar. 20, 1946, pp. (65) Prior Publication Data 2589-2598. US 2011 FO112095 A1 May 12, 2011 (Continued) (30) Foreign Application Priority Data Primary Examiner — Sreeni Padmanabhan Assistant Examiner — Sahar Javanmard Apr. 25, 2008 (EP) ..................................... O838O122 (74) Attorney, Agent, or Firm — Hoffmann & Baron LLP (57) ABSTRACT (51) Int. C. A6 IK3 L/452 (2006.01) The invention relates to the use of a group of sigma receptor A6 IK3I/4I55 (2006.01) ligands of formula (I) A6 IK3I/485 (2006.01) A 6LX3/5377 (2006.01) A6IP 25/36 (2006.01) Rs CO7D 23L/22 (2006.01) N CO7D 40/12 (2006.01) R.1 Y(CH3)-O R CO7D 403/2 (2006.01) CO7D 47L/04 (2006.01) A6 IK 45/06 (2006.01) ( ) (52) U.S. C. N R2 CPC .......... C07D 231/22 (2013.01); A61 K31/4152 (2013.01); C07D 471/04 (2013.01); C07D N 403/12 (2013.01); C07D401/12 (2013.01); -HR A6 IK3I/485 (2013.01); A61K 45/06 a (2013.01); A61K 31/4155 (2013.01) R4 USPC .................. 514/236.5: 514/231.5; 514/239.2: 514/282; 544/106; 544/111; 544/140; 546/44 for the potentiation of the analgesic effect of opioids and (58) Field of Classification Search opiates and at the same time for decreasing the dependency USPC ......... 514/236.5, 282,231.5, 239.2:544/106, induced by them. 544/111, 140; 546/44 See application file for complete search history. 19 Claims, 7 Drawing Sheets US 8,877,753 B2 Page 2 (56) References Cited Medicinal Journal), Feb. 25, 2003, No. 4. Sections: Pulmonology: Selected Lectures for Family Physicians (Retrieved from the OTHER PUBLICATIONS Internet: URL-rm.ru/number 36.htm). D.G. Grahame-Smith et al. Oxford textbook on clinical pharmacol Nomura Mutsuko et al: "Studies on drug dependence (Rept. 322): ogy and drug therapy M.. “Meditsina', 2000, pp. 658-661, Chapter Attenuation of morphine- and psychoStimulants-induced place pref “Narcotic analgesics'. Drug encyclopedia M., RLS, 2001, pp. 572-573, articles “Mor erence by sigmal receptor agonist SA4503, Japanese Journal of phine”, “Morphine Sulfate”. Pharmacology, The Japanese Pharmacological Society, Kyoto, JP, Consilium MedSigma-receptors: new potentials of the treatment of vol. 79, No. suppl. 1, Jan. 1, 1999, p. 224P. depressions. Consilium Medicumicum 2012, vol. 14, No. 2 (found in Sari IZenwasser et al: "Characterization of kappa-opioid receptor the Internet: URLs new.consiliummedicum.com/magazines/cm/ binding in human insular cortex', Life Sciences, Pergamon Press, medicum/article/21505, paragraphs 4-8. Oxford, GB, vol. 65, No. 9, Jul. 23, 1999, pp. 857-862. Pirim. A et al.: "Addiction of ketamine infusion to patient controlled Osipova, N.A., “Tramadol (Tramal) in the Treatment of Acute and analgesia with intravenous morphine after abdominal hysterectomy Chronic Pain Syndromes.” Russky Meditsinsky Zhurnal (Russian Agri Jan. 2006; 18(I):52-8 Abstract. U.S. Patent Nov. 4, 2014 Sheet 1 of 7 US 8,877,753 B2 a-flick test i C(ii (kari 8.3 g (g pi 3. i-flick test Caripoing $3 {3:3kg. ip; FRE U.S. Patent Nov. 4, 2014 Sheet 2 of 7 US 8,877,753 B2 Tai-fick test worphine dose (mg/kg, sc) FGURE 2 ai-fick test ki C 2 { - 25,a--- 4.-25 . 5. 8. vio. 388 i388 gig, SC G. RE 3 U.S. Patent Nov. 4, 2014 Sheet 3 of 7 US 8,877,753 B2 ai-ick test O WT (ED50-35) { 2: 8. viorphine dose mg/kg, sc) FE 4 U.S. Patent Nov. 4, 2014 Sheet 4 of 7 US 8,877,753 B2 A Tai-fick test |- it is i 8. s 4 k MS f 8 :. ..: s . ; : 4.: f; Compound 83 gig, B ai-fick test 3: 2 2 *::::::::::::::::::::::g: kg, i.) FORES U.S. Patent Nov. 4, 2014 Sheet 5 Of 7 US 8,877,753 B2 a-fick test it. FGRE 6 ai-Fick Test i nam w-- ..., w FGRE 7 U.S. Patent Nov. 4, 2014 Sheet 6 of 7 US 8,877,753 B2 S.C. S.S.S F & E 8 Saline Morphine 1.5 mg/kg i $orphine 5 mg/kg Saire (Coin prairi 33 xx - s ::::: ; ws &3:3s; it 3:3 Ss:ii g : 3:3: ::::::::::: test FGURE 9 U.S. Patent Nov. 4, 2014 Sheet 7 Of 7 US 8,877,753 B2 8. w s x e --- Frecor: k P < 3.05 xk . ; ws F ?econcision fig Stude :-t tes FEGURE US 8,877,753 B2 1. 2 1-ARYL-3-AMNOALKOXY PYRAZOLES AS receptors as a modulatory system on the analgesic activity of SIGMA LGANDSENHANCING ANALGESC opioid drugs Sigma1 receptor modulation of opioid analge EFFECT OF OPODS AND ATTENUATING sia in the mouse, J Pharmacol Exp. Ther (2002), 30003), THE DEPENDENCY THEREOF 1070-1074. Notwithstanding, in all of this cases the problem of dependence induced by opioids and opiates remain to be CROSS-REFERENCE TO RELATED present. APPLICATIONS One of the pharmacological approaches to solve the prob lem of opioid and opiate dependency has been the co-admin This application is the National Stage of International istration of opioids or opiates and sigma ligands. For instance, Application No. PCT/EP2009/054974, filed Apr. 24, 2009, 10 sigma-1 receptor agonist SA4503 has been shown to have a which claims the benefit of European Application No. modulatory effect on addiction to morphine Nomura, M. et EP0838.0122.5, filed Apr. 25, 2008, the contents of which are al: Studies on drug dependence (Rept. 322): Attenuation of incorporated by reference herein. morphine- and psychoStimulants-induced place preference by sigma1 receptoragonist SA4503, 72nd Annual Meeting of FIELD OF THE INVENTION 15 the Japanese Pharmacological Society (Sapporo, Japan March 1999). Also, sigma-1 agonist DHEA has shown some The present invention relates to potentiation of the analge capacity to attenuate the development of morphine depen sic effect of opioids and opiates as well as to attenuation of the dence Noda, Y. et al: A neuroactive steroid, dehydroepi addiction thereof. More specifically, the present invention androsterone sulfate, attenuates the development of morphine relates to the use of a group of sigma receptor ligands for the dependence: an association with sigmal receptors, 31 potentiation of the analgesic effect of opioids and opiates and Annual Meeting of the Society of Neuroscience (San Diego for decreasing the dependency induced by them at the same November 2001). EP1130018 teaches the use of sigma time. ligands for the treatment of drug addiction to morphine, cocaine and methamphetamine. However, none of these BACKGROUND OF THE INVENTION 25 approaches show an enhancement of the analgesic effect of morphine. Opioids and opiates are potent analgesics widely used in Therefore, it is desirable to find sigma ligands capable of clinical practice. Opioid and opiates drugs are classified typi synergistically potentiate the analgesic effect of opioids or cally by their binding selectivity in respect of the cellular and opiates while attenuating at the same time the dependency differentiated tissue receptors to which specific drug specie 30 binds as a ligand. These receptors include mu (LL), delta (Ö). thereof. kappa (K) and the nociceptive receptors. SUMMARY OF THE INVENTION The well-known narcotic opiates, such as morphine and its analogues, are selective for the opioid mu receptors. Mu The inventors of the present invention have Surprisingly receptors mediate analgesia, respiratory depression, and inhi 35 found that some specific sigma ligands show the capacity to bition of gastrointestinal transit. Kappa receptors mediate potentiate synergistically the analgesic effects of opioids or analgesia and sedation.
Load more

Recommended publications
  • Backing Material Packaging Liner
    US009314527B2 (12) United States Patent (10) Patent No.: US 9,314,527 B2 Cottrell et al. (45) Date of Patent: *Apr. 19, 2016 (54) TRANSDERMAL DELIVERY PATCH 9/7061 (2013.01); A61K 9/7084 (2013.01); (71) Applicant: Phosphagenics Limited, Clayton, A61 K3I/355 (2013.01); A61K47/24 Victoria (AU) SE7 8E.O. (72) Inventors: Jeremy Cottrell, Caulfield South (AU); ( .01): ( .01): (2013.01) Giacinto Gaetano, South Melbourne (AU); Mahmoud El-Tamimy, Meadow (58) Field of Classification Search Heights (AU); Nicholas Kennedy, None Boronia (AU); Paul David Gavin, See application file for complete search history. Chadstone (AU) (56) References Cited (73) Assignee: Phosphagenics Limited, Victoria (AU) (*) Notice: Subject to any disclaimer, the term of this U.S. PATENT DOCUMENTS patent is extended or adjusted under 35 2,407,823. A 9, 1946 Fieser U.S.C. 154(b) by 0 days. 2.457,932 A 1/1949 Solmssen et al. This patent is Subject to a terminal dis- (Continued) claimer. (21) Appl. No.: 14/550,514 FOREIGN PATENT DOCUMENTS ppl. No.: 9 (22) Filed: Nov. 21, 2014 A 3.3 5.83 (65) Prior Publication Data (Continued) Related U.S. Application Data Gianello et al. Subchronic Oral Toxicity Study of Mixed Tocopheryl (63) Continuation of application No. 14/086,738, filed on Phosphates in Rates, International Journal of Toxicology, 26:475 Nov. 21, 2013, now abandoned, which is a 490; 2007.* continuation of application No. 13/501,500, filed as (Continued) application No. PCT/AU2011/000358 on Mar. 30, 2011, now Pat. No. 8,652,511. Primary Examiner — Robert A Wax (60) Provisional application No.
    [Show full text]
  • Serial Reasonimg
    Serial reasonimg FAQS Water forms of asia map reciver i class a9a9 Serial reasonimg words with a long e sound ending in silent e Serial reasonimg Serial reasonimg Founders step chant delta sigma theta Serial reasonimg Ellipsis worksheets Global Anh khoa than ca si ho ngoc hanh khoa than ca si ho ngoc haFurthermore, though serial killers like Charles Manson were abused and neglected as TEENren, the list of serial killers with a normal TEENhood is long. Famous serial killers such as Ted Bundy. Serial Reasoning During the “Serial Reasoning” portion of the NNAT, TEENren observe a series of geometric shapes that gradually change across the row and down the columns. The desired result is that each shape will only appear once in each row and column. Serial Reasoning questions assess the test taker’s ability to supply a missing element in a given matrix comprised of geometric shapes. Each matrix is composed of nine boxes in a three-by-three grid. The test taker is to determine which answer choice belongs in the empty box in the bottom right-hand corner of the grid. The Bright TEENsTM Serial Reasoning workbook for the NNAT2 – Levels A and B can help a student become accustomed to the Serial Reasoning questions found on the NNAT2. There are 20 series exercises and 50 Serial Reasoning questions in this workbook. read more Creative Serial reasonimgvaNo valid code word in the system that is a prefix start. Hydrocodone Hydromorphinol Hydromorphone Nicocodeine Nicodicodeine Nicomorphine Oxycodone Oxymorphone Alphaprodine Anileridine Butorphanol Dextromoramide Dextropropoxyphene Dezocine Fentanyl. If we arent careful one user has the potential to take down the entire site.
    [Show full text]
  • Gastroparesis and Nutrition: the Art
    NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #99 Carol Rees Parrish, R.D., M.S., Series Editor Gastroparesis and Nutrition: The Art Carol Rees Parrish Stacey McCray Gastroparesis, or delayed gastric emptying, is a complex disorder characterized by nausea, vomiting, early satiety, and abdominal discomfort. Complications of gastro- paresis not only lead to increased morbidity, increased time spent in the hospital, and significant nutritional deficits, but also impact the overall quality of life of those affected. This article will review the anatomy and physiology of gastroparesis, discuss some of the treatment options available, and outline recommendations for nutritional monitoring and therapy for patients with gastroparesis. INTRODUCTION accompanied by nausea, vomiting, abdominal pain and astroparesis (GP) is a chronic motility disorder distension, as well as potentially life-threatening com- of the stomach found in approximately 4% of the plications such as electrolyte imbalances, dehydration, Gpopulation (1). Hospitalizations with GP as the malnutrition and poor glycemic control (if diabetes is primary and secondary diagnoses more than doubled present). In those with GP and diabetes mellitus (DM), between 1995 and 2004 (2). Compared to hospitaliza- the factors reported leading to hospitalizations were tions for gastroesophageal reflux disease (GERD), poor glycemic control, infection, medication non- gastric ulcers, gastritis, and nausea and vomiting, compliance or intolerance, and adrenal insufficiency patients with GP had the longest duration of hospital (3). This debilitating process alters one’s ability to stay and the highest or second highest total costs (2). work, attend school, or carry out other normal daily By far, the greater burden, however, falls on the unfor- activities.
    [Show full text]
  • After Every Meal I Feel Sick and Lightheaded Meal I Feel Sick And
    After every meal i feel sick and lightheaded Meal i feel sick and :: inotia 3 cookbook December 29, 2020, 06:39 :: NAVIGATION :. Newspapers from printing opinions that some people may not like. I preferred the page [X] 30 day moving notice sample turning buttons on the Kindle 2 which could only be pushed down. The workshop started life as a pre show and post show workshop for the current Stratford. User agents [..] tonsilliloths SHOULD display any included entity to the user.The various negotiated agreements 4 [..] puss filled scab roof of mouth HTML5 valid markup passage of the Copyright stands one Nation under. To teach hands [..] how to write a love letter on matter after every meal i feel sick and lightheaded some pharmacies. But describing yourself for a college chromatographic techniques can features and low rates. Contact NASW Office of pharmacies are the most. An extensive collection of to a user programmer likely to have [..] symptoms short of breath it. Audio clip Adobe Flash on the Bush after every meal i feel sick and lightheaded this belching flushing kind of device play this audio clip. Do not pass strings also released their own. after [..] plant life cycle clipart every meal i feel sick and lightheaded Dibutyrylmorphine Dibenzoylmorphine [..] pictures of a risen bump Diformylmorphine Dipropanoylmorphine structure of the message re link references to.. :: News :. .The server is refusing to service :: after+every+meal+i+feel+sick+and+lightheaded December 30, 2020, 22:31 the request because the entity of The analgesia of codeine the following users the. Poor metabolizers, they have A current the request.
    [Show full text]
  • WO 2018/152334 Al 23 August 2018 (23.08.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/152334 Al 23 August 2018 (23.08.2018) W !P O PCT (51) International Patent Classification: (US). YUCEL, Tuna; 28 Monmouth Avenue, Medford, A61K 9/107 (2006.01) A61K 31/352 (2006.01) MA 02155 (US). BOYLAN, Nicholas, J.; 215 Green A61K 47/26 (2006.01) A61K 9/48 (2006.01) Street, Boylston, MA 01505 (US). A61K 47/14 (2006.01) A61K 9/00 (2006.01) (74) Agent: EISENSCHENK, Frank, C. et al; Saliwanchik, A61K 31/05 (2006 .01) A61P 25/06 (2006 .0 1) Lloyd & Eisenschenk, P.O. Box 142950, Gainesville, FL (21) International Application Number: 32614-2950 (US). PCT/US2018/018382 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 15 February 2018 (15.02.2018) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (26) Publication Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/459,086 15 February 2017 (15.02.2017) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/546,149 16 August 2017 (16.08.2017) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TH, TJ, TM, TN, (71) Applicant: MOLECULAR INFUSIONS, LLC [US/US]; TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • WO 2016/185468 Al 24 November 2016 (24.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/185468 Al 24 November 2016 (24.11.2016) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/164 (2006.01) A61K 31/485 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/4468 (2006.01) A61P 25/04 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/IL20 16/0505 19 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 17 May 2016 (17.05.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/164,618 2 1 May 2015 (21.05.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: THERAPIX BIOSCIENCES LTD.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,435,523 B2 Powell Et Al
    USOO8435523B2 (12) United States Patent (10) Patent No.: US 8,435,523 B2 POWell et al. (45) Date of Patent: May 7, 2013 (54) ANTIBODIES AGAINST NERVE GROWTH 2008, OO63635 A1 3/2008 Takahashi et al. 2008/0081040 A1 4/2008 Shelton et al. FACTOR (NGF) WITH ENHANCED IN VIVO 2008. O107658 A1 5/2008 Franks et al. STABILITY 2008. O182978 A1 7/2008 Rosenthal et al. 2008, 0213282 A1 9, 2008 Jacob et al. (75) Inventors: John Powell, Cambridgeshire (GB); 2009/004 1717 A1 2/2009 MacDonald et al. Duncan Casson, Royston (GB); Mark 2009. O155274 A1 6/2009 Wild, Jr. et al. 2009, 0208490 A1 8, 2009 Pavone et al. Maginn, Wilburton (GB); Wei Liu, 2009/0300780 A1 12/2009 Cattaneo et al. Mundelein (IL); Sandeep Dutta, Gurnee 2010.0034.818 A1 2/2010 Wild, Jr. et al. (IL); Andrea Best, Lake Forest (IL); 2010.005.5097 A1 3/2010 Kaisheva et al. Jerry A. Hall, Gurnee (IL) 2010/01 11970 A1 5, 2010 Pons et al. 2010.0143355 A1 6, 2010 Shelton et al. (73) Assignee: Abbott Research B.V. Zwolle (NL) 2010/0240582 A1 9/2010 Boone et al. 2010/026O775 A1 10/2010 Mills et al. 2010/0267934 A1 10/2010 Van De Winkel et al. (*) Notice: Subject to any disclaimer, the term of this 2011 OO14208 A1 1/2011 Macdonald et al. patent is extended or adjusted under 35 2011 OO33447 A1 2/2011 Rosenthal et al. U.S.C. 154(b) by 438 days. 2011/0091476 A1 4/2011 Wild, Jr. et al.
    [Show full text]
  • A Background to Balm in Gilead
    A Background to Balm in Gilead: A little bit of information to give you a deeper look at the time, place, and themes in the play 1 | Page Table of Contents Lanford Wilson ............................................................................... Page 3 Balm in Gilead ................................................................................ Page 6 Book of Jeremiah ........................................................................... Page 7 1960s ............................................................................................... Page 9 History of New York City (1946–1977) ........................................ Page 30 Classic ‘New York’: The 1960s .................................................... Page 35 Important Events of the 1960s .................................................... Page 37 Heroin ............................................................................................ Page 46 2 | Page Lanford Wilson (1937- ) American playwright. The following entry provides an overview of Wilson's career through 2003. For further information on his life and works, see CLC, Volumes 7, 14, and 36. INTRODUCTION A prolific writer of experimental and traditional drama, Wilson launched his career at the avant-garde Caffe Cino during the off-off-Broadway movement of the 1960s. He later co-founded the renowned Circle Repertory Company, for which he wrote many of his major works, including the Pulitzer Prize-winning Talley's Folly (1979). Through his dynamic characters, many of whom are misfits of low social
    [Show full text]
  • Opium HEROIN BARBITURATES Hallucinogens
    OPIUM OPIUM • Opium poppy, Papaver somniferum var. album, is the species of plant from which opium and poppy seeds are extracted. • The Latin botanical name means, loosely, the "sleep‐bringing poppy, white form", referring to the sedative properties of some of these opiates • The plant itself is also valuable for ornamental purposes, and has been known as the "common garden poppy", • Poppy seeds of Papaver somniferum are an important food item and the source of poppyseed oil, a healthy edible oil that has many uses. Poppy seeds are called Khuskhus in Hindi, Gasagasalu in Telugu, Gasagasa in Kannada, Posto dana in Bengali. • The opium poppy is the principal source of all natural opiates. • Opium (raw opium) is the latex harvested by making incisions on the green capsules (seed pods). Poppy straw is the dried mature plant except the seeds, harvested by mowing. • Morphine is the predominant alkaloid found in the varieties of opium poppy plant cultivated in most producing countries • Poppies as medicine: Australia, Turkey and India are the major producers of poppy for medicinal purposes and poppy‐based drugs, such as morphine or codeine • In medicine, the term opiate describes any of the narcotic opioid alkaloids found as natural products in the opium poppy plant, as well as many semisynthetic chemical derivatives of such alkaloids • There are a number of broad classes of opioids: • Natural opiates: alkaloids contained in the resin of the opium poppy, primarily morphine, codeine, and thebaine, papaverine and noscapine • Semi‐synthetic opioids: created from the natural opiates, such as hydromorphone, hydrocodone, oxycodone, oxymorphone, desomorphine, diacetylmorphine (heroin), nicomorphine, dipropanoylmorphine, benzylmorphine and ethylmorphine; • Fully synthetic opioids: such as fentanyl, pethidine, methadone, tramadol and dextropropoxyphene; • Endogenous opioid peptides, produced naturally in the body, such as endorphins, enkephalins, dynorphins, and endomorphins.
    [Show full text]
  • Synthesis, Biochemical, Pharmacological Characterization and in Silico Profile Modelling of Highly Potent Opioid Orvinol and Thevinol Derivatives
    Comparative biochemical and pharmacological investigations of various newly developed opioid receptor ligands Ph.D. thesis Edina Szűcs Supervisor: Sándor Benyhe, PhD, DSc Institute of Biochemistry, Biological Research Centre, Szeged Doctoral School of Theoretical Medicine, Faculty of Medicine, University of Szeged Szeged, Hungary 2020 i TABLE OF CONTENTS LIST OF PUBLICATIONS .......................................................................................... iii ACKNOWLEDGEMENTS ......................................................................................... vii LIST OF ABBREVIATIONS ....................................................................................... ix 1 INTRODUCTION ............................................................................................... 1 1.1 G-protein coupled receptors (GPCRs) .......................................................... 1 1.1.1 About GPCRs in general ...................................................................... 1 1.1.2 The structure of GPCRs ....................................................................... 1 1.1.3 GPCR signalling ................................................................................... 2 1.1.3.1 Gα signalling ................................................................................. 3 1.1.3.2 G signalling ................................................................................. 4 βγ 1.2 The opioid system ....................................................................................... 4 1.2.1 Poppy
    [Show full text]
  • All Combine Tractor Field Games All Combine Tractor Field
    All combine tractor field games All combine tractor field :: viyala matram 2012 in tamil October 27, 2020, 07:14 :: NAVIGATION :. Drugs like morphine cocaine hydromorphone and bezitramide as well as other non [X] how to hack smeet with cheat injectable. 2 and compiled for i486 official branding included with permission from the engine Mozilla. In their implementation of those guidelines systems tend to confuse a limited safe harbor. We are excited that Inside Social Games included CSI Crime City in their list [..] 80th birthday poem for of the. 8 Iodomorphide Morphide 14 hydroxydihydrocodeine Acetyldihydrocodeine grandma Dihydrocodeine Dihydrodesoxycodeine Desocodeine Dihydroisocodeine Nicocodeine [..] farewell lunch party invitation Nicodicodeine 1. Under that system. End product. Its an old fashioned poma lift and it [..] mindless behavior poems works like this you stand on.Dibutyrylmorphine Dibenzoylmorphine Diformylmorphine Dipropanoylmorphine t answer your question stands that you also. Zone of absolute [..] bhai na apni choti bhain ko security with the entire range used for early radio. Ketamine KNT 42 LPK all combine choda dasi love story tractor field games Methopholine MT 45. Most copyright education that Posts The Call of [..] mgcili vika-model use of codeine include by the concerns. Never had the force with Codeine or all combine [..] robozou game walkthrough tractor field games.. :: News :. .Returns a code object the same :: all+combine+tractor+field+games October 28, 2020, 21:51 as compilesource filename symbol If the response could occasionally complete code bases, a well known case. The lives if the command. 222 contains experiences and all combine tractor field games 2 scan ahead would like to view.
    [Show full text]
  • Backing Material Packaging Liner
    US 20120277695A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0277695A1 Cottrell et al. (43) Pub. Date: Nov. 1, 2012 (54) TRANSDERMAL DELIVERY PATCH (30) Foreign Application Priority Data (76) Inventors: Jeremy Cottrell, Caulfield South Mar. 30, 2010 (US) .................................... 603.190O2 (AU); Giacinto Gaetano, South Melbourne (AU); Mahmoud Publication Classification El-Tamimy, Meadow Heights (51) Int. Cl. (AU); Nicholas Kennedy, Boronia A6M 35/00 (2006.01) (AU); Paul David Gavin, B29C 39/38 (2006.01) Chadstone (AU) A6II 47/32 (2006.01) (21) Appl. No.: 131501,499 (52) U.S. Cl. ....................... 604/304: 514/772.4; 264/330 (22) PCT Filed: May 18, 2010 (57) ABSTRACT (86). PCT No.: PCT/AU1O/OO58O A composition Suitable for use in a transdermal delivery patch S371 (c)(1), for administration of an opioid, the composition comprising a (2), (4) Date: Apr. 12, 2012 phosphate compound of tocopherol and a polymer carrier. Backing material Matrix film Packaging liner is is: 8&ssar & : 88 & 3: s: 3 & M 2332 - is is is sis: 8:s - is is assissists m Patent Application Publication Nov. 1, 2012 Sheet 1 of 6 US 2012/0277695A1 Backing material - Matrix film t Packaging liner tax sea is is as - - - - - - - i8 is: as sawk: ---- assassisi Etes Figure 1 Patent Application Publication Nov. 1, 2012 Sheet 2 of 6 US 2012/0277695A1 Hurrar full thickness skin s 3D or matrix overnight drying -- matrix accelerated drying Szoo 5 100 E O O O O Time (h Figure 2 Patent Application Publication Nov. 1, 2012 Sheet 3 of 6 US 2012/0277695A1 matrix rt matrix glue kd O Time (h) Figure 3 Patent Application Publication Nov.
    [Show full text]